RA Capital Management and Boxer Capital led a $125m series B2 round in iTeos.

Private equity firms RA Capital Management and Boxer Capital led a $125m series B2 financing round in iTeos Therapeutics, a biotechnology company. Additional investors include MPM Capital, Societe Regionale d'Investissement de Wallonie, HBM Partners, The Federal Holding and Investment Company, The Invus Group, VIVES, 6 Dimensions Capital, RTW Investments, Fund+, Janus Henderson Investors, and Curative Ventures Management. "We are very pleased to have the strong support of this leading class of investors who share our excitement for the highly innovative oncology therapies we have developed at iTeos. We look forward to accelerating and expanding our clinical development efforts to identify the most promising indications and combinations for people suffering with cancer. This financing maximizes our ability to execute our development plans alone or in partnership," Michel Detheux, iTeos President and CEO.